About

Dr. Shu obtained his PhD degree in 1998 at the Institute of Virology, Chinese Academy of Preventive Medicine. He got post-doctoral training at the Institute of Gene Therapy, Mount Sinai Medical School (1998–1999), and in Department of Molecular Pharmacology Medical School, University of California, Los Angeles (1999–2002). He is currently the director of WHO Collaborating Center for Reference and Research on Influenza (WHO CC), the director of Chinese National Influenza Centre (CNIC), the deputy director of National Institute for Viral Disease Control and Prevention of China CDC.
Dr. Shu has been committed to the research of influenza since 2002, and has made great contributions for influenza prevention and control in the world. He played a leadership to establish the national influenza surveillance network in China, which is the biggest influenza network in the world including 408 influenza laboratories and 554 influenza sentinel hospitals. He also led the CNIC to be designated as the first WHOCC in developing countries by WHO in 2010. He has lead more than 20 scientific projects supported by China central government agencies, National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), USA, et al. He published more than100 peer-reviewed scientific journal papers including in Science, Nature, NEJM, Lancet et al. Dr. Shu firstly identified a novel avian H7N9 and H10N8 influenza virus caused severe human infections in China that has not been detected in humans and animals previously, with great global public health concern.
Dr. Shu was the winner for National Science and Technology progress award and the China Youth Science and technology prize, He was selected as the National Science and Technology Innovation Leader in 2012 and named as the Science and Technology Innovator in 2014.